Long-Term Safety and Efficacy of Repeat Treatments of DaxibotulinumtoxinA for Injection in Adults With Isolated Cervical Dystonia (ASPEN-OLS)

Approximately 350 adult subjects will be recruited from approximately 80 study centers in the
United States, Canada, and Europe who were enrolled in the ASPEN-1 Study Protocol 1720302 and
de novo subjects (not previously enrolled in ASPEN-1 Study Protocol 1720302) will be treated
with up to 4 different doses of daxibotulinumtoxinA for injection.

Inclusion Criteria:

- Meets diagnostic criteria for isolated CD (idiopathic; dystonic symptoms localized to
the head, neck, shoulder areas) with at least moderate severity at Baseline (Day 1),
defined as a TWSTRS-total score of at least 20, with at least 15 on the
TWSTRS-Severity subscale, at least 3 on the TWSTRS-Disability subscale, and at least 1
on the TWSTRS-Pain subscale (minimum TWSTRS subscale criteria applicable only to
subjects not previously enrolled in Study Protocol 1720302)

- Subjects who were previously enrolled in Study Protocol 1720302, and completed the
study, including:

- Those with no reduction or have an increase from baseline in the average
TWSTRS-total score at Weeks 4 and 6 (i.e., no improvement or worsened disease
status), and the investigator agreed that there was a need for retreatment based
on the subject's symptoms and neurologic exam findings

- Those who benefited from study treatment and completed follow-up study visits up
to the time point of when their TWSTRS - total score reached/exceeded their
target TWSTRS score

- Those who benefited from study treatment but subsequently experienced significant
recurrence of CD symptoms (e.g. pain) during the study before their TWSTRS-total
score reached their target TWSTRS score and requested retreatment, which the
investigator determined was warranted based on the subject's symptoms and
neurologic exam findings

- Those who completed study visits up to Week 36 and their TWSTRS-total score never
reached their target TWSTRS score and they never requested another treatment. The
investigator determined that these subjects can be followed in the OLS until
their TWSTRS-total score is the same or higher than their target TWSTRS score or
until they request retreatment, which the investigator determined is clinically
indicated

- De novo subjects (not previously enrolled in Study Protocol 1720302):

- Naïve to BoNT treatment

- BoNT treatment-experienced; if previously treated with BoNTA, the subject must
have demonstrated a clinically meaningful response to the last BoNTA treatment
based on the clinical judgment of the investigator

Exclusion Criteria:

- Cervical dystonia attributable to an underlying etiology, (e.g., traumatic torticollis
or tardive torticollis)

- Predominant retrocollis or anterocollis CD

- Significant dystonia in other body areas, or is currently being treated with botulinum
toxin (BoNT) for dystonia in areas other than those associated with isolated CD

- Severe dysphagia (Grade 3 or 4 on the Dysphagia Severity Scale) at Screening or
Baseline (prior to study treatment)

- Any neuromuscular neurological conditions that may place the subject at increased risk
of morbidity with exposure to BoNT, including peripheral motor neuropathic diseases
(e.g., amyotrophic lateral sclerosis and motor neuropathy, and neuromuscular
junctional disorders such as Lambert-Eaton syndrome and myasthenia gravis)

- Previous treatment with any BoNT product for any condition within the 14 weeks prior
to Screening (applicable only to de novo subjects)

- Botulinum neurotoxin treatment-experienced subjects who had suboptimal or no treatment
response to the most recent BoNTA injection for CD, as determined by the investigator;
or history of primary or secondary non-response to BoNTA injections, known to have
neutralizing antibodies to BoNTA; or have a history of botulinum toxin type B
(rimabotulinumtoxinA [Myobloc/Neurobloc]) injection for CD due to non-response or
suboptimal response to BoNTA (applicable only to de novo subjects)